Grifols SA, founded in 1940 and headquartered in Barcelona, Spain, is a global healthcare company dedicated to improving the health and well-being of people through the development of life-saving therapies. The company specializes in the collection and processing of human plasma and offers a range of products for the treatment of various medical conditions, particularly in the fields of hematology, immunology, and infectious diseases.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| GRFSM 2.25% 2027-11-15 EURGrifols SA | Spain | 2027-11-15 | 2.250 | 2.49 |
| GRFSM 2.25% 2027-11-15 EURGrifols SA | Spain | 2027-11-15 | 2.250 | 2.49 |
| GRFSM 3.20% 2025-05-01 EURGrifols SA | Spain | 2025-05-01 | 3.200 | — |
| GRFSM 3.20% 2025-05-01 EURGrifols SA | Spain | 2025-05-01 | 3.200 | — |
| GRFSM 3.88% 2028-10-15 EURGrifols SA | Spain | 2028-10-15 | 3.875 | 4.12 |
| GRFSM 3.88% 2028-10-15 EURGrifols SA | Spain | 2028-10-15 | 3.875 | 4.12 |
| GRFSM 4.75% 2028-10-15 USDGrifols SA | Spain | 2028-10-15 | 4.750 | 5.20 |
| GRFSM 4.75% 2028-10-15 USDGrifols SA | Spain | 2028-10-15 | 4.750 | 5.21 |
| GRFSM 7.13% 2030-05-01 EURGrifols SA | Spain | 2030-05-01 | 7.125 | 5.89 |
| GRFSM 7.13% 2030-05-01 EURGrifols SA | Spain | 2030-05-01 | 7.125 | 5.89 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Grifols has been active in the bond market since the early 2000s, with significant issuances that include a €600 million bond offering in 2021 to finance acquisitions and strengthen its balance sheet. Currently, its bonds have yields that are competitive within the healthcare sector, reflecting strong market confidence. Grifols' bonds often feature callable options, providing flexibility in managing debt. Recent news of a strategic partnership has further solidified investor interest in their fixed-income offerings.